Quest Diagnostics Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics (NYSE: DGX) has introduced the AD-Detect™ Test for Alzheimer's Disease, the first consumer-initiated blood test for assessing potential risk of developing Alzheimer's disease. The test is available for purchase on questhealth.com.
July 31, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has launched a new product, the AD-Detect™ Test for Alzheimer's Disease. This could potentially increase the company's revenues if the product is well received by consumers.
The introduction of a new product, especially one that is first-to-market, can potentially increase a company's revenues if it is well received by consumers. Given the increasing prevalence of Alzheimer's disease and the need for early detection, this product could be in high demand, which would positively impact Quest Diagnostics' stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100